Mass General Brigham: BEST-CLI Clinical Trial Indicates Optimal Treatment for Patients with Limb Threatening Ischemia
November 08, 2022
November 08, 2022
BOSTON, Massachusetts, Nov. 8 (TNSres) -- Mass General Brigham issued the following news release:
More than 200 million people worldwide have peripheral artery disease (PAD) and more than 1-in-10 have a severe form of PAD known as chronic limb threatening ischemia (CLTI), putting them at risk of leg amputation, cardiovascular disease and death.
Two forms of treatment -- surgical bypass (Bypass) and endovascular therapy (Endo) -- are commonly used to restore blood flow . . .
More than 200 million people worldwide have peripheral artery disease (PAD) and more than 1-in-10 have a severe form of PAD known as chronic limb threatening ischemia (CLTI), putting them at risk of leg amputation, cardiovascular disease and death.
Two forms of treatment -- surgical bypass (Bypass) and endovascular therapy (Endo) -- are commonly used to restore blood flow . . .